Search Clinical Trials
Sponsor Condition of Interest |
---|
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
Colorectal Neoplasms
Endometrial Neoplasms
Ovarian Neoplasms
Pancreatic Neoplasms
The purpose of this study is to find out whether the study drug, LY3537982, is safe and
effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients
must have already received or were not able to tolerate the standard of care, except for
specific groups who have not had... expand
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years. Type: Interventional Start Date: Jul 2021 |
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma
Primary CNS Lymphoma
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib
monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in
combination with one of two different high dose methotrexate based regimens
(methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/
vincristine)... expand
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B) Type: Interventional Start Date: Dec 2021 |
Non-Invasive Monitoring of Traumatic Brain Injury Progression Using the Infrascanner (MOBI-1)
University of Alabama at Birmingham
Brain Injuries, Traumatic
MOBI-1 is a multicenter clinical trial that will evaluate the use of the Infrascanner for
the monitoring of traumatic intracranial hematomas. expand
MOBI-1 is a multicenter clinical trial that will evaluate the use of the Infrascanner for the monitoring of traumatic intracranial hematomas. Type: Observational Start Date: Apr 2022 |
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
Forma Therapeutics, Inc.
Sickle Cell Disease
This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of
etavopivat and test how well etavopivat works compared to placebo to improve the amount
of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when
the blood vessels become blocked and... expand
This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain). Type: Interventional Start Date: Mar 2021 |
Evolutionary Therapy for Rhabdomyosarcoma
H. Lee Moffitt Cancer Center and Research Institute
Rhabdomyosarcoma
This clinical trial will evaluate 4 different strategies of chemotherapy schedules in
newly diagnosed participants with metastatic Fusion Positive (alveolar) Rhabdomyosarcoma.
The participant and their physician will choose from: Arm A) a first strike therapy, Arm
B) a first strike-second strike (maintenance)... expand
This clinical trial will evaluate 4 different strategies of chemotherapy schedules in newly diagnosed participants with metastatic Fusion Positive (alveolar) Rhabdomyosarcoma. The participant and their physician will choose from: Arm A) a first strike therapy, Arm B) a first strike-second strike (maintenance) therapy, Arm C) an adaptively timed therapy, and Arm D) conventional chemotherapy. Type: Interventional Start Date: Sep 2020 |
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
Seagen Inc.
Myelodysplastic Syndrome
Acute Myeloid Leukemia
This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out
if it is safe for patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia
(AML). It will study SEA-CD70 to find out what its side effects are and if it works for
AML and MDS. A side effect is anything... expand
This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out if it is safe for patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It will study SEA-CD70 to find out what its side effects are and if it works for AML and MDS. A side effect is anything the drug does besides treating cancer. This study will have six groups or "parts." - Part A will find out how much SEA-CD70 should be given to patients. - Part B will use the dose found in Part A to find out how safe SEA-CD70 is and if it works to treat patients with MDS. - Part C will use the dose found in Part A to find out how safe SEA-CD70 is and if it works to treat patients with AML. - Part D will find out how much SEA-CD70 with azacitidine should be given to patients. - Part E will use the dose found in Part D to find out how safe SEA-CD70 with azacitidine is and if it works to treat patients with MDS or MDS/AML that has not been treated. - Part F will use the dose found in Part D to find out how safe SEA-CD70 with azacitidine is and if it works to treat patients with MDS or MDS/AML. Type: Interventional Start Date: Aug 2020 |
A Peer-Led Intervention to Improve Postpartum Retention in HIV Care
University of Pennsylvania
HIV/AIDS
The purpose of this study is to test the efficacy of a theory-driven peer intervention
for pregnant and postpartum women living HIV. The peer intervention is designed to
increase self-efficacy, social support, self-regulatory behaviors, and outcome expectancy
in order to improve retention in care... expand
The purpose of this study is to test the efficacy of a theory-driven peer intervention for pregnant and postpartum women living HIV. The peer intervention is designed to increase self-efficacy, social support, self-regulatory behaviors, and outcome expectancy in order to improve retention in care and viral suppression postpartum. The intervention will consist of face-to-face prenatal educational sessions, starting in early third trimester, and postpartum sessions scheduled up to three months postpartum. Type: Interventional Start Date: Mar 2020 |
An Exercise Intervention to Improve Overall Brain Health
University of Alabama at Birmingham
Brain Care Score
Exercise
Hypertension
BMI
The goal of this clinical trial is to test the effects of 10 weeks of exercise on overall
brain health, reduction in blood pressure, and the number of blood vessels in the back of
the eyes in patients with hypertension and have a body mass index ≥ 25 kg/m2. The main
question[s] it aims to answer are:... expand
The goal of this clinical trial is to test the effects of 10 weeks of exercise on overall brain health, reduction in blood pressure, and the number of blood vessels in the back of the eyes in patients with hypertension and have a body mass index ≥ 25 kg/m2. The main question[s] it aims to answer are: - To test the effect of moderate vs intensive exercise on Brain Care Score outcomes. - To ascertain the differential impact of moderate vs high intensity exercise in reducing hypertension and its downstream effects. Type: Interventional Start Date: Jan 2024 |
Study on Use of Omega-3 Fatty Acids to Improve Outcomes in Individuals With Sickle Cell Disease
University of Alabama at Birmingham
Sickle Cell Disease
Sickle cell disease (SCD) is associated with significant morbidity and mortality. Pain
and many adverse outcomes occurring in sickle cell disease are inflammatory driven.
Recent data has shown that gut dysbiosis is present in individuals with sickle cell
disease. Gut dysbiosis has been linked to inflammation... expand
Sickle cell disease (SCD) is associated with significant morbidity and mortality. Pain and many adverse outcomes occurring in sickle cell disease are inflammatory driven. Recent data has shown that gut dysbiosis is present in individuals with sickle cell disease. Gut dysbiosis has been linked to inflammation in certain diseases. Omega -3-fatty acids (fish oil) has been shown to improve pain outcomes in individuals with sickle cell disease, but its acceptance is variable. The aim of this study is to determine if a plant-based omega-3-fatty acids will be more acceptable and also improve outcomes in individuals with sickle cell disease Type: Interventional Start Date: Aug 2023 |
Quadriceps Tendon Versus Bone Patellar Tendon Bone Autograft ACL Reconstruction RCT
University of Alabama at Birmingham
Orthopedic Disorder
Anterior Cruciate Ligament Injuries
The choice of autograft for ACL reconstruction continues to be debated. To date, there
has only be one completed randomized controlled trial with quad tendon to BTB and the
tendon included a bone plug. There has been no study to date comparing an all soft tissue
quad tendon to patellar tendon in a... expand
The choice of autograft for ACL reconstruction continues to be debated. To date, there has only be one completed randomized controlled trial with quad tendon to BTB and the tendon included a bone plug. There has been no study to date comparing an all soft tissue quad tendon to patellar tendon in a randomized controlled trial for ACL reconstruction. Type: Interventional Start Date: Sep 2023 |
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly...
National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
This phase III trial compares the effect of usual treatment of chemotherapy and steroids
and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab.
Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability
of cancer cells to grow and spread. The... expand
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care. Type: Interventional Start Date: Jan 2021 |
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer...
National Cancer Institute (NCI)
Bladder Adenocarcinoma
Bladder Clear Cell Adenocarcinoma
Bladder Mixed Adenocarcinoma
Bladder Neuroendocrine Carcinoma
Bladder Small Cell Neuroendocrine Carcinoma
This phase II trial studies how well cabozantinib works in combination with nivolumab and
ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from
where it first started (primary site) to other places in the body. Cabozantinib may stop
the growth of tumor cells by blocking... expand
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone. Type: Interventional Start Date: May 2019 |
UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy
University of Alabama at Birmingham
Alzheimer Disease
The primary objective of this study is to measure the concentration and the regional
brain distribution of pathologic amyloid deposition using the PET tracer [C-11]PiB in
participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions
between race and vascular risk factors, brain... expand
The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer [C-11]PiB in participants in the UAB Alzheimer's Disease Center cohort. Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with [C-11]PiB-PET, and cognitive status will be the primary outcome of this imaging study. Type: Interventional Start Date: Apr 2018 |
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative...
ECOG-ACRIN Cancer Research Group
CD20 Positive
Mantle Cell Lymphoma
This randomized phase III trial studies rituximab after stem cell transplant and to see
how well it works compared with rituximab alone in treating patients with in minimal
residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal
antibodies, such as rituximab, may interfere... expand
This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving rituximab with or without stem cell transplant may work better in treating patients with mantle cell lymphoma. Type: Interventional Start Date: Mar 2018 |
Refining the Role of Mid-induction Bone Marrow Biopsy in Acute Myeloid Leukemia: A Pilot Study
University of Alabama at Birmingham
Acute Myeloid Leukemia
The purpose of the study is to observe the outcomes of patients with acute myeloid
leukemia who do not receive an immediate second round of chemotherapy after undergoing a
standard mid-induction bone marrow biopsy. expand
The purpose of the study is to observe the outcomes of patients with acute myeloid leukemia who do not receive an immediate second round of chemotherapy after undergoing a standard mid-induction bone marrow biopsy. Type: Observational Start Date: May 2024 |
Cord Clamping Among Neonates With Congenital Heart Disease
Carl Backes, MD
Congenital Heart Disease (CHD)
The goal of this clinical trial is to compare 2 different timepoints for clamping the
umbilical cord at birth for term-born infants with a prenatal diagnosis of congenital
heart disease (CHD). The main questions it aims to answer are:
- Does Delayed Cord Clamping at 120 seconds (DCC-120) or Delayed... expand
The goal of this clinical trial is to compare 2 different timepoints for clamping the umbilical cord at birth for term-born infants with a prenatal diagnosis of congenital heart disease (CHD). The main questions it aims to answer are: - Does Delayed Cord Clamping at 120 seconds (DCC-120) or Delayed Cord Clamping at 30 seconds (DCC-30) after birth lead to better health outcomes? - Does DCC-120 seconds or DCC-30 seconds after birth lead to better neuromotor outcomes at 22-26 months of infant age (postnatal)? Participants will be asked to do the following: - Participate in either DCC-120 or DCC-30 at birth (randomized assignment). - Complete General Movements Assessment (GMA) at 3-4 months of infant age (postnatal), complete questionnaires / surveys at this time. - Complete questionnaires / surveys at 9-12 months of infant age (postnatal). - Complete Hammersmith Infant Neurological Examination (HINE), Developmental Assessment of Young Children 2 Edition (DAYC-2), and questionnaires / surveys at 22-26 months of infant age (postnatal). - Permit data collection from electronic medical records for both the mother and infant study participants. Investigators will compare DCC-120 vs. DCC-30 to see which approach is more beneficial to both the mother and baby with CHD. Type: Interventional Start Date: Dec 2023 |
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast...
ECOG-ACRIN Cancer Research Group
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
HER2-Positive Breast Carcinoma
Invasive Breast Carcinoma
This phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG)
positron emission tomography/computed tomography (PET/CT) works in predicting response to
standard of care chemotherapy prior to surgery in patients with HER2-positive stage
IIa-IIIc breast cancer. FDG is a radioactive... expand
This phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG) positron emission tomography/computed tomography (PET/CT) works in predicting response to standard of care chemotherapy prior to surgery in patients with HER2-positive stage IIa-IIIc breast cancer. FDG is a radioactive tracer that is given in a vein before PET/CT imaging and helps to identify areas of active cancer. PET and CT are imaging techniques that make detailed, computerized pictures of areas inside the body. The use of FDG-PET/CT may help doctors better decide if a patient needs more or less treatment before surgery in order to get the best response. This study evaluates whether FDG-PET/CT is useful in predicting a patient's response to standard of care chemotherapy. Type: Interventional Start Date: May 2023 |
Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders Among Hospitalized...
Columbia University
Injection Site Infection
Substance Use Disorders
The goal of this clinical trial is to test the effectiveness of an integrated infectious
disease/substance use disorder (SUD) clinical team intervention approach in patients
hospitalized with severe injection-related infections (SIRI) who use drugs. The main
question this study aims to answer is whether... expand
The goal of this clinical trial is to test the effectiveness of an integrated infectious disease/substance use disorder (SUD) clinical team intervention approach in patients hospitalized with severe injection-related infections (SIRI) who use drugs. The main question this study aims to answer is whether this intervention approach will be associated with lower mortality and fewer hospital readmissions. Participants will participate in the integrated SUD/ID care team intervention (SIRI Team). Researchers will compare this intervention to treatment as usual (TUA) to see if there are any differences in health outcomes. Type: Interventional Start Date: Jan 2024 |
Cardiometabolic Health Intervention Using Movement-to-Music Exercise
University of Alabama at Birmingham
Cardiometabolic Risk Factors in Adult Wheelchair Users
The study aims to test the benefits of a 24-week, cardio-emphasized Movement-to-Music
exercise program for reversing cardiometabolic health risk factors compared to
asynchronous, standard exercise programs among 132 adult wheelchair users. The targeted
cardiometabolic health factors are waist circumference,... expand
The study aims to test the benefits of a 24-week, cardio-emphasized Movement-to-Music exercise program for reversing cardiometabolic health risk factors compared to asynchronous, standard exercise programs among 132 adult wheelchair users. The targeted cardiometabolic health factors are waist circumference, triglycerides, "good" cholesterol, glucose, and blood pressure. Additionally, a 12-week follow-up phase (weeks 25-36) is included to see whether the gains are maintained. Type: Interventional Start Date: Sep 2023 |
Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Celgene
Leukemia, Myeloid
This Phase 1, clinical study of CC-96191 will explore the safety, tolerability and
preliminary biological and clinical activity of CC-96191 as a single-agent in the setting
of Relapsed or refractory acute myeloid leukemia (R/R AML).
The dose escalation (Part A) of the study will explore escalating... expand
This Phase 1, clinical study of CC-96191 will explore the safety, tolerability and preliminary biological and clinical activity of CC-96191 as a single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML). The dose escalation (Part A) of the study will explore escalating intravenous doses of CC-96191 to estimate the MTD and/or RP2D of CC-96191 as monotherapy. The expansion (Part B), will further evaluate the safety and efficacy of CC-96191 administered at or below the MTD in one or more expansion cohorts in order to determine the RP2D. Type: Interventional Start Date: Jun 2021 |
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma...
Caribou Biosciences, Inc.
Lymphoma, Non-Hodgkin
Relapsed Non Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Non Hodgkin Lymphoma
Lymphoma
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and
immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma
after lymphodepletion consisting of cyclophosphamide and fludarabine. expand
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine. Type: Interventional Start Date: May 2021 |
Respiratory Outcomes After Early Vitamin D Supplementation in Infants Born Extremely Preterm
University of Alabama at Birmingham
Prematurity; Extreme
This is a masked randomized clinical trial in which extremely preterm infants fed human
milk will be randomly assigned to receive either the highest (intervention group) or
lowest (control group) vitamin D dose recommended during the first 14 days after birth. expand
This is a masked randomized clinical trial in which extremely preterm infants fed human milk will be randomly assigned to receive either the highest (intervention group) or lowest (control group) vitamin D dose recommended during the first 14 days after birth. Type: Interventional Start Date: Mar 2023 |
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
Fusion Pharmaceuticals Inc.
Pancreatic Ductal Adenocarcinoma (PDAC)
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Gastric Cancer
Ewing Sarcoma
This is a first-in-human Phase 1 clinical trial designed to investigate the safety,
tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and
[111In]-FPI-2058 in participants with neurotensin receptor 1 (NTSR1)-expressing solid
tumours. expand
This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 in participants with neurotensin receptor 1 (NTSR1)-expressing solid tumours. Type: Interventional Start Date: Feb 2023 |
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting...
National Cancer Institute (NCI)
Recurrent Biliary Tract Carcinoma
Recurrent Distal Cholangiocarcinoma
Recurrent Gallbladder Carcinoma
Recurrent Intrahepatic Cholangiocarcinoma
Stage III Distal Bile Duct Cancer AJCC v8
This phase II ComboMATCH treatment trial compares the usual treatment of modified
leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) chemotherapy to using binimetinib
plus mFOLFOX6 chemotherapy to shrink tumors in patients with biliary tract cancers that
have spread to other places in the body (advanced)... expand
This phase II ComboMATCH treatment trial compares the usual treatment of modified leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) chemotherapy to using binimetinib plus mFOLFOX6 chemotherapy to shrink tumors in patients with biliary tract cancers that have spread to other places in the body (advanced) and had progression of cancer after previous treatments (2nd line setting). Fluorouracil is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It works by killing tumor cells. Leucovorin may help the other drugs in the mFOLFOX6 chemotherapy regimen work better by making tumor cells more sensitive to the drugs. Binimetinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals tumor cells to multiply. This helps to stop or slow the spread of tumor cells. Giving binimetinib in combination with mFOLFOX6 chemotherapy may be effective in shrinking or stabilizing advanced biliary tract cancers in the 2nd line setting. Type: Interventional Start Date: Feb 2024 |
Constraint-Induced Movement Therapy for Adults Post-Stroke With Mild Upper Extremity Impairment
University of Alabama at Birmingham
CVA (Cerebrovascular Accident)
Stroke
Upper Extremity Paresis
Constraint-Induced Therapy (CI Therapy) is a behavioral approach to neurorehabilitation
and consists of multi-components that have been applied in a systematic method to improve
the use of the limb or function addressed in the intensive treatment. CI Therapy for the
more-affected upper extremity (UE)... expand
Constraint-Induced Therapy (CI Therapy) is a behavioral approach to neurorehabilitation and consists of multi-components that have been applied in a systematic method to improve the use of the limb or function addressed in the intensive treatment. CI Therapy for the more-affected upper extremity (UE) post-stroke is administered in daily treatment sessions over consecutive weekdays. Sessions include motor training with repeated, timed trials using a technique called shaping, a set of behavioral strategies known as the Transfer Package (TP) to improve the use of the more-affected hand in the life situation, and strategies to remind participants to use the more-affected UE including restraint. Robust improvements in the amount and qualify of use have been realized with stroke participants from mild-to-severe UE impairment. Type: Interventional Start Date: Dec 2022 |
- Previous
- Next